Current cancer immunotherapies are primarily predicated on αβ T cells, with a stringent
dependence on MHC-mediated presentation of tumour-enriched peptides or unique …

The intricacy of diseases, shaped by intrinsic processes like immune system exhaustion and
hyperactivation, highlights the potential of immune renormalization as a promising strategy …

Immune-based therapies such as immune checkpoint inhibitors have revolutionized the
systemic treatment of various cancer types. The therapeutic application of monoclonal …

Simple Summary The IL-12 family cytokines play an important role in regulating the tumor
immune contexture. Recent efforts geared towards the development of better immune …

The potential of cancer immunotherapy relies on the mobilization of immune cells capable of
producing antitumour cytokines and effectively killing tumour cells. These are major …

γδ T cells represent a substantial fraction of intestinal lymphocytes at homeostasis, but they
also constitute a major lymphocyte population infiltrating colorectal cancers (CRCs); …

Immunotherapies targeting conventional T cells have revolutionized systemic treatment for
many cancers, yet only a subset of patients benefit from these approaches. A better …

With the promise of T cell-based therapy for cancer finally becoming reality, this Review
focuses on the less-studied γδ T cell lineage and its diverse responses to tumours. γδ T cells …

Immunotherapy is now the standard of care for advanced hepatocellular carcinoma (HCC),
yet many patients fail to respond. A major unmet goal is the boosting of T-cells with both …

IL-17, a potent proinflammatory cytokine, has been shown to intimately contribute to the
formation, growth, and metastasis of a wide range of malignancies. Recent studies implicate …